Enveda Biosciences

Based in California, US, and founded in 2019 by CEO Viswa Colluru, Enveda Therapeutics, Inc. , d/b/a Enveda Biosciences is a biotechnology company that uses a uses a drug platform to construct and decode integrated datasets of anthropological, biological, and chemical information from medicinal plants to inspire new medicines. In September 2025, Enveda Biosciences raised USD 150 million in series D funding led by Premji Invest, with participation from other investors Baillie Gifford, Dimension, FPV Ventures, Kinnevik, Level Ventures, Lingotto Investment Management, Lux Capital, IA Ventures, Peakline Partners, and Socium Ventures. The series D funding values Enveda Biosciences at USD 997.

15 million post-money. As part of the transaction, Mikael Dolsten will join the company's board of directors. Enveda Biosciences uses advanced technology to leverage natural products for drug discovery. The company’s platform identifies and harnesses the diverse chemical properties and biological activities found in nature, which traditional small molecule libraries cannot match.

Enveda's approach includes discovering new medicines by exploring novel chemistries to manipulate disease-relevant proteins and uncovering new drug targets through the study of natural compounds. The firm’s pipeline focuses on therapies for inflammation, fibrosis, pain, and dermatological conditions, utilizing both oral and topical formulations. Enveda's technology platform overcomes challenges in bioactivity annotation and structure elucidation, providing a prolific source of next-generation compounds. The company plans to use its proceeds from September 2025 funding to advance clinical trials for its lead drug candidates, expand its pipeline of plant-derived small molecules, and support regulatory filings.